Sugi Predict

Sugi Predict / Compounds / SCHEMBL1844446

SCHEMBL1844446

SCHEMBL1844446

C[C@]1(F)C(O)O[C@H](COC(=O)c2ccccc2)[C@H]1OC(=O)c1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.50
▸ POLB P06746 2/20 0.42
▸ MAPK1 P28482 2/20 0.42
▸ GAA P10253 2/20 0.42
▸ NPSR1 Q6W5P4 1/20 0.42
▸ LMNA P02545 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ USP2 O75604 1/20 0.41
▸ NPC1 O15118 1/20 0.40
▸ TDP1 Q9NUW8 2/20 0.40
▸ MAPT P10636 1/20 0.40
▸ HIF1A Q16665 1/20 0.39
▸ SLC6A2 P23975 1/20 0.39
▸ SLC6A3 Q01959 1/20 0.39
▸ SYNJ2 O15056 3/20 0.39
▸ HTT P42858 1/20 0.39
▸ LGALS9 O00182 1/20 0.39
▸ LGALS1 P09382 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19326429 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL15127206 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL1844450 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL929484 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL13187913 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL19326334 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL1844448 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL18271833 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL17453216 1.00 ALDH1A1 (0.50) ALDH1A1POLBMAPK1GAANPSR1
SCHEMBL2481853 0.88 UPP1 (0.47) ALDH1A1POLBGAANPSR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11642361-B2 Nucleoside phosphoramidate prodrugs GILEAD SCIENCES, INC. (US) 2023-05-09 — — US disclosed
WO-2023069495-A1 OLIGONUCLEOTIDES WITH 2'-DEOXY-2'-F-2'-C-METHYL NUCLEOTIDES ALNYLAM PHARMACEUTICALS, INC. (US) 2023-04-27 — — WO disclosed
US-20210196741-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS GILEAD PHARMASSET LLC 2021-07-01 — — US disclosed
EP-3797782-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTIONS Janssen BioPharma, Inc. (US) 2021-03-31 — — EP disclosed
EP-3497111-A2 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen BioPharma, Inc. (US) 2019-06-19 — — EP disclosed
US-20190169221-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Biopharma, Inc. 2019-06-06 — — US disclosed
US-10183037-B2 Nucleoside phosphoramidate prodrugs GILEAD PHARMASSET LLC (US) 2019-01-22 — — US disclosed
WO-2018031818-A2 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF ALIOS BIOPHARMA, INC. (US) 2018-02-15 — — WO disclosed
US-9815864-B2 Substituted nucleosides, nucleotides and analogs thereof ALIOS BIOPHARMA, INC. (US) 2017-11-14 — — US disclosed
US-20170143749-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF Janssen Biopharma, Inc. 2017-05-25 — — US disclosed
US-7964580-B2 Nucleoside phosphoramidate prodrugs PHARMASSET, INC. (US) 2011-06-21 — — US disclosed
EP-2324043-A1 NUCLEOSIDE DERIVATIVES AS INHIBITORS OF VIRAL POLYMERASES Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) 2011-05-25 — — EP disclosed
WO-2010026153-A1 NUCLEOSIDE DERIVATIVES AS INHIBITORS OF VIRAL POLYMERASES ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2010-03-11 — — WO disclosed
US-20100016251-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PHARMASSET, INC. (US) 2010-01-21 — — US disclosed
US-20100016251-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PHARMASSET, INC. (US) 2010-01-21 — — US disclosed
WO-2009115893-A2 NOVEL NUCLEOSIDE DERIVATIVES HETERO RESEARCH FOUNDATION (IN) 2009-09-24 — — WO disclosed
WO-2009115893-A2 NOVEL NUCLEOSIDE DERIVATIVES HETERO RESEARCH FOUNDATION (IN) 2009-09-24 — — WO disclosed
US-20090233879-A1 NOVEL NUCLEOSIDE DERIVATIVES HETERO DRUGS LIMITED (IN) 2009-09-17 — — US disclosed
US-20090233879-A1 NOVEL NUCLEOSIDE DERIVATIVES HETERO DRUGS LIMITED (IN) 2009-09-17 — — US disclosed
WO-2008121634-A2 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PHARMASSET, INC. (US) 2008-10-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016251-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PNP, NUDT1, TYMP ALDH1A1 1168/4885POLB 293/4885MAPK1 1804/4885
US-20170143749-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NT5C3B, TYMP ALDH1A1 2325/4885POLB 441/4885MAPK1 2678/4885
US-20190169221-A1 SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF PNP, NUDT1, NT5C3B ALDH1A1 2186/4885POLB 207/4885MAPK1 3869/4885
US-11642361-B2 Nucleoside phosphoramidate prodrugs PNP, NUDT1, TYMP ALDH1A1 1168/4885POLB 293/4885MAPK1 1804/4885
US-20090233879-A1 NOVEL NUCLEOSIDE DERIVATIVES ENTPD5, PNP, ENTPD1 ALDH1A1 2855/4885POLB 291/4885MAPK1 2887/4885
US-20210196741-A1 NUCLEOSIDE PHOSPHORAMIDATE PRODRUGS PNP, NUDT1, TYMP ALDH1A1 1168/4885POLB 293/4885MAPK1 1804/4885
US-10183037-B2 Nucleoside phosphoramidate prodrugs PNP, NUDT1, TYMP ALDH1A1 1168/4885POLB 293/4885MAPK1 1804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.